Eurofins Genomics Achieves GLP Certification – A First for a Genomics Service Provider in Germany

Eurofins Genomics, the genomics division of the Eurofins Scientific Group and international market leader in genomic services, has now achieved Good Laboratory Practice (GLP) certification for DNA sequencing services, the first genomic service provider in Germany to attain such qualification.

Good Laboratory Practice is a required standard for laboratories conducting non-clinical safety studies, for example, toxicology and pharmacology studies in animals. It is also required for non-clinical safety studies for the development of drugs, small molecules, vaccines and gene therapeutics. GLP standards are also critical for the development of diagnostic kits and device validation (FDA and patent submissions), the analyses of production strains and GMO plants like genetic stability testing (e.g. analysis of inserted DNA and its transcripts, etc.). Eurofins Genomics is GLP certified for “DNA sequencing for genotyping and safety testing of GMOs, microorganisms, viruses, cell banks and cell lines”. With this certificate, Eurofins Genomics offers not only Sanger sequencing services under GLP, but also next generation sequencing (NGS) applications.

“This GLP certification is one of the highest QM/QA certifications that can be achieved for non-clinical analyses. We are very proud to be the first genomic service provider within Germany to have achieved this very ambitious goal,” says Peter Persigehl, General Manager Eurofins Genomics Europe. “The GLP accreditation is a great success. It is the result of the efforts over the past years to continuously improve the Eurofins Genomics quality standards.”

“With the addition of the certified GLP standard to our DNA sequencing portfolio, Eurofins Genomics is even more able to provide services with the highest demand of regulatory authorities quality,” says Bruno Poddevin, Senior Vice President Eurofins Genomics.